Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Luca Carlino1, Peter C Astles1, Bryony Ackroyd2

  • 1Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.

PubMed
Summary

Researchers identified potent inhibitors targeting the NSD2-PWWP1 domain, a crucial protein in cancer. This discovery offers new tools for studying nuclear receptor-binding SET domain 2 (NSD2) dysregulation and developing targeted cancer therapies.